Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Multicriteria Decision Analysis (MCDA) In HTA - Pilot Study in the Czech Republic.

Autor: Hajek P; Pfizer s r. o., Prague, Czech Republic., Pecen L; CEEOR s. r. o., Prague, Czech Republic., Bulejova L; InterMune, Muttenz, Switzerland., Cook M; BAYER s. r. o., Prague, Czech Republic., Dolezal T; VALUE OUTCOMES, Prague, Czech Republic., Dolezel J; GlaxoSmithKline, s. r. o., Prague, Czech Republic., Duba J; OAKS Consulting s. r. o., Prague 9, Czech Republic., Dukova I; Merck, Prague, Czech Republic., Fuksa L; General Health Insurance Company of the Czech Republic, Praha, Czech Republic., Heislerova M; University Hospital in Motol, Prague, Czech Republic., Jaskova K; Merck, Prague, Czech Republic., Karasek P; Novartis s. r. o., Prague, Czech Republic., Klimes J; iHETA, Prague, Czech Republic., Kminek A; AstraZeneca, Prague, Czech Republic., Kucera Z; Sanofi-Aventis, Prague, Czech Republic., Vesela Š; Janssen, Prague, Czech Republic., Vothova P; Pfizer s r. o., Prague, Czech Republic., Svihovec J; University Hospital in Motol, Prague, Czech Republic.

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2014 Nov; Vol. 17 (7), pp. A439. Date of Electronic Publication: 2014 Oct 26.